Viking Therapeutics' VK2735 Drug Maintains Weight Loss
📊 LLY — Piyasa Yorumu
▼ down · 60%News that Viking Therapeutics' obesity drug VK2735 can maintain weight loss could weaken LLY's (Eli Lilly) competitive position. LLY stock closed at 1167.25, up 1.9% in the last 24 hours, with RSI at 58, not near overbought territory, but MACD maintains a positive signal. The news could create short-term selling pressure, particularly by raising market share concerns for LLY's tirzepatide (Mounjaro/Zepbound) product. Although technical indicators still support an upward trend, I assess that downside risk has increased over a 1-3 day period due to the news flow. Nevertheless, for a definitive bearish signal, a price drop below the SMA20 (1156.79) should be monitored.
📊 NVO — Piyasa Yorumu
▼ down · 60%Positive news regarding Viking Therapeutics' VK2735 drug could intensify competition in the obesity and weight management market, potentially pressuring Novo Nordisk (NVO) stock. NVO is already in a strong downtrend: a nearly 8% decline in the last 24 hours, with RSI14 at 24 in oversold territory and MACD below the negative signal line, confirming short-term weakness. The price is trading below the 20 and 50-day moving averages, indicating that selling pressure may continue. Although the news does not directly impair NVO's fundamental outlook, the efficacy of a rival drug could negatively affect investor sentiment. Oversold conditions may lead to short-term rebound buying, but the overall trend is downward.